Influence of CYP2D6 Genotypes and Phenotypes on the Plasma Levels and Clinical Response to Aripiprazole. [PDF]
Gras C +14 more
europepmc +1 more source
Influence of combined CYP2C19 and CYP2D6 phenotypes on adverse drug reactions in patients with major depressive disorder: a clinical cohort study. [PDF]
Görnert C +6 more
europepmc +1 more source
Blood will tell: plasma biomarkers in isolated REM sleep behavior disorder. [PDF]
Ibrahim A, Süzgün MA, Stefani A.
europepmc +1 more source
Design considerations for C9orf72 disease prevention trials. [PDF]
Benatar M +23 more
europepmc +1 more source
Stratification Tools for Disease-Modifying Trials in Prodromal Synucleinopathy [PDF]
Morbelli, S.
core +1 more source
Cholinergic degeneration in prodromal and early Parkinson's disease: a link to present and future disease states. [PDF]
Eisenstein T +9 more
europepmc +1 more source
CYP2D6 Phenotype as a Predictor of Adverse Drug Reactions in Patients Treated With Trazodone: An Explorative Pharmacogenetic Study. [PDF]
Wiss FM +7 more
europepmc +1 more source
The role of tissue-based biomarkers in isolated REM sleep behavior disorder: implications for early detection and prognostication. [PDF]
Baumgartner AJ, Amara AW.
europepmc +1 more source
REM Sleep Behavior Disorder as a Prodromal Synucleinopathy: Updates on Clinical and Laboratory Biomarkers, and Implications for Neuroprotective Trials. [PDF]
Neilson LE, Khattab YI, Lim MM.
europepmc +1 more source
Skin-Based α-Synuclein Deposits Detection Across the Prodromal Continuum of Synucleinopathies: Updated Evidence and Perspectives. [PDF]
Fereshtehnejad SM.
europepmc +1 more source

